Filing Flows › ImmunityBio (IBRX) › Q3 2026
ImmunityBio (IBRX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
ImmunityBio (IBRX) reported revenue of $48.8M for the third quarter 2026 (Q3 2026), +52% from a year earlier and -5% from the quarter before. Operating margin was -159.7%, net loss $185M (377.9% of revenue).
ImmunityBio, Q3 2026: revenue $48.8M (+52% year over year), operating margin -159.7%, net loss $185M, operating cash flow −$75.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $48.8M | -5% | +52% |
| Operating profit | −$78.0M | — | — |
| Net earnings | −$185M | — | — |
| Operating cash flow | −$75.3M | — | — |
What changed
Revenue was $48.8M in Q3 2026, up 52% year over year and down 5% from the previous quarter.
Operating costs exceeded revenue by $78.0M, an operating margin of -159.7%. Total costs grew 45% against revenue growth of 52%. The fastest-growing cost line was Cost of revenue (+629%). The quarter ended with a net loss of $184.6M, narrower than the previous quarter's $230.4M loss. Net interest and other expense of $106.6M was the main reason.
Operating cash flow was −$75.3M. Non-cash charges added back $3.9M of depreciation and amortization and $8.7M of share-based compensation. Working capital and other items added $96.6M. Capital expenditures of $2.9M exceeded it, leaving free cash flow of −$78.3M.
Questions
What was ImmunityBio's revenue in the third quarter 2026?
ImmunityBio (IBRX) reported revenue of $48.8M for the third quarter 2026 (Q3 2026), +52% from a year earlier and -5% from the quarter before.
Was ImmunityBio profitable in the third quarter 2026?
Operating loss was $78.0M (-159.7% of revenue) and net loss $185M.
Source: ImmunityBio 10-Q on SEC EDGAR.